Loading...
Adjuvant chemotherapy after resection of pancreatic cancer includes either 6 months of modified FOLFIRINOX, the preferred option, or the combination of gemcitabine and capecitabine. Investigators now report the results of an industry-sponsored, randomized, phase 3 trial comparing 6 months of adjuvant gemcitabine to the combination of gemcitabine and nab-paclitaxel after resection of pancreatic cancer.
Of 866 patients, median age was 64 and 56% were male. Most patients had primaries of the head of the pancreas (81%), were node positive (72%), and had a normal carbohydrate antigen 19-9 level (80%); a minority had surgical margins <1 mm from the tumor (26%).
At a median follow-up of 38.5 months, the combination of gemcitabine/nab-paclitaxel did …